Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 14/20 | 0.48 |
| ▸ | RCOR1 | Q9UKL0 | 8/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 2/20 | 0.39 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833876 | 0.97 | KDM1A (0.49) | KDM1ARCOR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6814917 | 0.86 | AKR1C2 (0.48) | KDM1ARCOR1ALB | |
| SCHEMBL6834194 | 0.85 | SRD5A2 (0.52) | KDM1ARCOR1MAOAALB | |
| SCHEMBL6835702 | 0.85 | MAPT (0.47) | ALB | |
| SCHEMBL6834267 | 0.82 | KDM1A (0.42) | KDM1ARCOR1MAOAALB | |
| SCHEMBL6707752 | 0.82 | KDM1A (0.43) | KDM1ARCOR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6835632 | 0.82 | TRPA1 (0.39) | KDM1ARCOR1MAOAALB | |
| SCHEMBL6708917 | 0.81 | KDM1A (0.43) | KDM1ARCOR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6834029 | 0.80 | KDM1A (0.42) | KDM1ARCOR1ALB | |
| SCHEMBL6833872 | 0.79 | KDM1A (0.43) | KDM1ARCOR1MAOAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | KDM1A 371/4885RCOR1 3086/4885SLC6A2 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.